Helicobacter pylori and interleukin-8 in gastric cancer

Table 1 Inhibitors targeting interleukin-8 in cancer progression

Inhibitors	Mechanisms	Ref.
Resveratrol	Reduces ROS, inhibits MAPK, AP-1 and NF-κB	[82,83]
Anthocyanin	Reduces ROS, inhibits MAPK, AP-1 and NF-κB	[84-86]
Apigenin	Increases the IκBα and thus inhibits NF-κB	[88,89]
RK-I-123	Reduces ROS and inhibits AP-1 and NF-κB	[91]
DA-6034	Dissociates IKK/HSP90 complex and inhibits NF-κB	[92,93]
Rebamipide	Prevents PLD expression via NF-κB	[94,95]
Gefitinib [Iressa™]	Inhibits EGFR	[98,99]
L. bulgaricus	Inhibits TLR4	[101]
L. acidophilus	Dissociates IKK/Hsp90 complex and inhibits NF-κB	[65,103]
NRF peptide	Disrupts interaction of NRF and NF-κB	[105]
miR-146	Negatively regulates IL-8	[110,111]
miR-155	Inhibits MyD88 via NF-κB	[112,115]
G31P	Synthetic derivative of IL-8	[117]
SCH-527123	CXCR2 inhibitor	[118]

IκBα: Inhibitor of kappa B alpha; RK-I-123: Phenyl-thiophenyl propenone; DA-6034: 7-Carboxymethyloxy-3’,4’,5-trimethoxy flavone; HSP: Heat shock Protein; PLD: Phospholipase D; EGFR: Epidermal growth factor receptor; NRF: NF-κB repressing factor: IL-8: Interleukin-8; miR: MicroRNAs; MAPK: Mitogen-activated protein kinase; IKK: IκB kinase; AP-1: Activator protein-1; ROS: Reactive oxygen species; TLR4: Toll-like receptor 4.